|
SCIENCE NEWS
Researchers Make Stem Cells From Developing Sperm
Scientists have identified key molecular players responsible for how adult cells revert back into a primordial, stem cell state in fruit fly sperm cells. [Johns Hopkins University School of Medicine, Baltimore]
Tumor Suppressor Pulls Double Shift as Reprogramming Watchdog
Salk researchers have uncovered that the tumor suppressor p53, not only stops cells that could become cancerous in their tracks but also controls somatic cell reprogramming. [Salk Institute for Biological Studies, San Diego]
Scientists Find Common Trigger in Cancer and Normal Stem Cell Production
Researchers at the School of Medicine have discovered, for the first time, a common molecular pathway that is used by both normal stem cells and cancer stem cells when they reproduce themselves. [Stanford School of Medicine, Stanford]
Non-insulin-producing Alpha Cells in the Pancreas can be Converted to Insulin-producing Beta Cells
In findings that add to the prospects of regenerating insulin-producing cells in people with type 1 diabetes, researchers have shown that insulin-producing beta cells can be derived from non-insulin-producing cells in the pancreas. [Max-Planck Institute for Biophysical Chemistry, Munich]
Researcher Discovers Genetic Circuit that Regulates Behavior of Stem Cells
European researchers have discovered that that embryonic stem cells are in a state of biochemical repose, static, awaiting a signal that causes them to differentiate is not correct, and that in fact the state of pluripotentiality in stem cells is anything but static. [Universitat Politecnica de Catalunya, Terrassa]
VIDEO: Researchers Identify Phosphorylated Signaling Proteins in Human Embryonic Stem Cells
Investigators have made the first comparative, large-scale phosphoproteomic analysis of human embryonic stem cells and their differentiated derivatives. [Burnham Institute for Medical Research , Burnham]
Aldagen Reaches Agreement With FDA on a Special Protocol Assessment for Phase 3 Trial of ALD-301 for Critical Limb Ischemia
The Phase 3 trial will be a double blind, placebo-controlled study designed to assess the ability of ALD-301 to improve clinical outcomes in patients with CLI, including amputation rates, ulcer healing and pain reduction. [Aldagen, Inc., Durham]
Two Lines Account for Most Human Embryonic Stem Cell Research
For the past eight years, scientists who wanted to use federal funds for research on human embryonic stem cells had to restrict their studies to 21 cell lines approved by the National Institutes of Health. But an analysis by a researcher at the Stanford University School of Medicine suggests that only two of those lines have been used routinely. [Stanford School of Medicine, Stanford]
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
|
|
INDUSTRY NEWS
Connexon Creative Launches Cord Blood News
Cord Blood News is a weekly e-newsletter that keeps members of the cord blood community informed by providing the latest news from all areas of the field, including its science, research, policy, and business.
University Hospitals Case Medical Center Selects STEMSOFT Software for Entire BMT Program
STEMSOFT Software Inc, the leading provider of software solutions for cell therapy transplant programs, is pleased to announce the licensing of STEMSOFT's complete suite of applications to the University Hospitals Case Medical Center. [STEMSOFT, Vancouver]
Opexa Announces Stem Cell Agreement with Novartis
Opexa Therapeutics, Inc recently announced that it has entered into an exclusive agreement with Novartis for the further development of Opexa's novel stem cell technology. [Opexa Therapeutics, Inc, The Woodlands]
DARA BioSciences, Inc. and America Stem Cell, Inc. Collaborate On Stem Cell Research
DARA BioSciences, Inc. announced recently that the Company is collaborating with America Stem Cell to expand on observations from recent preclinical studies showing that dipeptidylpeptidase inhibitors improve the efficiency of hematopoietic stem cell transplants. [DARA BioSciences, Raleigh]
Athersys Looking for Commercial Partners to Advance Stem Cell, Drug Therapies
Biopharmaceutical company Athersys Inc. is looking for commercial partners to help it develop and test its stem cell and drug therapies aimed at treating a variety of health problems. [Athersys Inc., Cleveland]
Millipore Licenses Novel Stem Cell Technology from Boston University
Boston University and Millipore Corporation recently announced a licensing agreement for a highly efficient method for creating induced Pluripotent Stem cells derived from mouse fibroblasts by using a single virus vector instead of multiple viruses in the reprogramming process. [Millipore, Billerica]
Pluristem's Award from the Israeli Office of the Chief Scientist Increased to $2.3 Million
Pluristem Therapeutics Inc. will receive a total of $2.3 million in funding for its stem cell programs from the Ministry of Industry, Trade and Labor of Israel; an increase from the previously announced amount of $1.9 million. [Pluristem, Haifa]
BMTbase(TM) 4 Beta Version Released
Completely redesigned from the ground up using .NET technology, version 4 is a browser-based application allowing for easier user access, deployment and more robust database management and security. (STEMSOFT, Vancouver)
|
|
POLICY NEWS
Two Lines Account for Most Human Embryonic Stem Cell Research
For the past eight years, scientists who wanted to use federal funds for research on human embryonic stem cells had to restrict their studies to 21 cell lines approved by the National Institutes of Health. But an analysis by a researcher at the Stanford University School of Medicine suggests that only two of those lines have been used routinely. [Stanford School of Medicine, Stanford]
Legislature to Duke It Out Over Stem Cell Regulations
Opponents of embryonic stem cell research in Michigan have mobilized to push for proposals requiring in-vitro fertilization patients to sign a consent form that addresses issues such as potential excess embryos, costs to store leftover embryos and a statement on the prohibition of accepting anything valuable in exchange for frozen embryos.
|
|
EVENTS
World Stem Cell Summit 2009
September 23-25, 2009
Baltimore, United States
TERMIS 2nd World Congress 2009
August 31 - September 3, 2009
Seoul, South Korea
Neuroscience 2009
October 17-21, 2009
Chicago, United States
Alzheimer's Disease Beyond Abeta
January 10-15, 2010
Copper Mountain, United States
Molecular Medicine Tri-Conference 2010
February 3-5, 2010
San Francisco, United States
ISSCR 8th Annual Meeting
June 16-19, 2010
San Francisco, United States
|
|
|
This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada |
|
|
